Book contents
- Maternal Hemodynamics
- Maternal Hemodynamics
- Copyright page
- Contents
- Contributors
- Section 1 Physiology of Normal Pregnancy
- Section 2 Pathological Pregnancy: Screening and Established Disease
- Section 3 Techniques: How To Do
- Section 4 Cardiovascular Therapies
- Chapter 15 Treatment Options for Hypertension in Pregnancy
- Chapter 16 Aspirin
- Chapter 17 Vascular Endothelial Growth Factor Gene Therapy in the Management of Cardiovascular Problems in Pregnancy
- Chapter 18 Nitric Oxide Donors in Preeclampsia
- Chapter 19 Vasodilatation and Fluid Expansion
- Section 5 Controversies
- Index
- Plate Section (PDF Only)
- References
Chapter 16 - Aspirin
from Section 4 - Cardiovascular Therapies
Published online by Cambridge University Press: 28 April 2018
Book contents
- Maternal Hemodynamics
- Maternal Hemodynamics
- Copyright page
- Contents
- Contributors
- Section 1 Physiology of Normal Pregnancy
- Section 2 Pathological Pregnancy: Screening and Established Disease
- Section 3 Techniques: How To Do
- Section 4 Cardiovascular Therapies
- Chapter 15 Treatment Options for Hypertension in Pregnancy
- Chapter 16 Aspirin
- Chapter 17 Vascular Endothelial Growth Factor Gene Therapy in the Management of Cardiovascular Problems in Pregnancy
- Chapter 18 Nitric Oxide Donors in Preeclampsia
- Chapter 19 Vasodilatation and Fluid Expansion
- Section 5 Controversies
- Index
- Plate Section (PDF Only)
- References
- Type
- Chapter
- Information
- Maternal Hemodynamics , pp. 161 - 170Publisher: Cambridge University PressPrint publication year: 2018
References
Patrono, C, Collar, B, Dalen, J et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998;114:470S–488S.Google Scholar
Farivar, RS, Brecher, P. Salicylate is a transcriptional inhibitor of the inducible nitric oxide synthase in cultured cardiac fibroblasts. J Biol Chem 1996;271:31585–92.CrossRefGoogle ScholarPubMed
Bradlow, BA, Chetty, N. Dosage frequency for suppression of platelet function by low dose aspirin therapy. Thromb Res 1982;27:99–110.Google Scholar
Patrignani, P, Filabozzi, P, Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366 –72.Google Scholar
Duley, L, Meher, S, Hunter, K, Askie, L. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev 2018 (in press).Google Scholar
Roberts, JM, Hubel, CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30 Suppl A:S32–7.Google Scholar
Young, BC, Levine, RJ, Karumanchi, SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010;5:173–92.CrossRefGoogle ScholarPubMed
Pijnenborg, R, Bland, JM, Robertson, WB, et al. Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta 1983;4: 397–413.CrossRefGoogle ScholarPubMed
Viinikka, L, Hartikainen-Sorri, AL, Lumme, R, et al. Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin thromboxane balance in mother and newborn. Br J Obstet Gynaecol 1993;100: 809–15.Google Scholar
Schiff, E, Peleg, E, Goldenberg, M, et al. The use of aspirin to prevent pregnancy induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. New Engl J Med 1989;321: 351–6.CrossRefGoogle ScholarPubMed
Benigni, A, Gregorini, G, Frusca, T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy induced hypertension. New Engl J Med 1989;321:357–62.CrossRefGoogle ScholarPubMed
Johnson, RD, Polakoski, K, Everson, WV, et al. Aspirin induces increased expression of both prostaglandin H synthase-1 and prostaglandin H synthase-2 in cultured human placental trophoblast. Am J Obstet Gynecol 1997;177(1):78–85.CrossRefGoogle ScholarPubMed
Han, CS, Mulla, MJ, Brosens, JJ, et al. Aspirin and heparin effect on basal and antiphos-pholipid antibody modulation of trophoblast function. Obstet Gynecol 2011;118(5):1021–8.Google Scholar
Bose, P, Black, S, Kadyrov, M, et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005;192(1):23–30.Google Scholar
Owen, J, Maher, JE, Hauth, JC, et al. The effect of low-dose aspirin on umbilical artery Doppler measurements. Am J Obstet Gynecol 1993;169(4):907–11.CrossRefGoogle ScholarPubMed
Bar, J, Hod, M, Pardo, J, et al. Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound Obstet Gynecol 1997;9(4):262–5.CrossRefGoogle ScholarPubMed
Grab, D, Paulus, WE, Erdmann, M, et al. Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol. 2000;15(1):19–27.CrossRefGoogle ScholarPubMed
Haapsamo, M, Martikainen, H, Räsänen, J. Low-dose aspirin reduces uteroplacental vascular impedance in early and mid gestation in IVF and ICSI patients: a randomized, placebo-controlled double-blind study. Ultrasound Obstet Gynecol 2008;32(5):687–93CrossRefGoogle ScholarPubMed
Cusick, W, Salafia, CM, Ernst, L, et al. Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. Am J Reprod Immunol 1995;34(3):141–7.Google Scholar
Tarim, E, Bal, N, Kilicdag, E, et al. Effects of aspirin on placenta and perinatal outcomes in patients with poor obstetric history. Arch Gynecol Obstet 2006;274:209–14.Google Scholar
Askie, LM, Duley, L, Henderson-Smart, DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791–8.Google Scholar
Baron, JA, Senn, S, Voelker, M, et al. Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. Drugs R D 2013;13:9–16.CrossRefGoogle ScholarPubMed
Kozer, E, Nifkar, S, Costei, A, et al. Aspirin consumption during the first trimester of pregnancy and congenital abnormalities: a meta-analysis. Am J Obstet Gynaecol 2002;187:1623–30.Google Scholar
Duckitt, K, Harrington, D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330(7491):565.CrossRefGoogle ScholarPubMed
Akolekar, R, Syngelaki, A, Poon, L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagnosis and Therapy 2013;33(1):8–15.CrossRefGoogle ScholarPubMed
Rolnik, DL, Wright, D, Poon, LC, O'Gorman, N, Syngelaki, A, de Paco, Matallana C, Akolekar, R, Cicero, S, Janga, D, Singh, M, Molina, FS, Persico, N, Jani, JC, Plasencia, W, Papaioannou, G, Tenenbaum-Gavish, K, Meiri, H, Gizurarson, S, Maclagan, K, Nicolaides, KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017 Aug 17;377(7):613–622.Google Scholar
Roberge, S, Nicolaides, K, Demers, S, et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013;41(5):491–9.CrossRefGoogle ScholarPubMed
Meher, S, Duley, L, Hunter, K et al. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017;216(2):121–8.Google Scholar
Neubauer, H, Kaiser, AF, Endres, HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance–the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011;9:3.Google Scholar
Rey, E, Rivard, G-E. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet, Gynecol Reprode Biol 2011;157(1):38–42.Google Scholar
Wojtowicz, A, Undas, A, Huras, H, et al. Aspirin resistance may be associated with adverse pregnancy outcomes. Neuro Endocrinol Lett 2011;32(3):334–9.Google Scholar